DD insider files Form 144 to sell 92,248 NYSE shares via Merrill Lynch

Rhea-AI Filing Summary

Form 144 notice for DuPont de Nemours, Inc. (DD) reports a proposed sale of 92,248 shares of Common stock through Merrill Lynch at 3455 Peachtree Road NE, Atlanta, GA, with an aggregate market value of $7,525,332.00. The filing lists the approximate date of sale as 09/04/2025 and the securities exchange as the NYSE.

The table of acquisition history shows most shares were received as compensatory stock awards from DuPont de Nemours, Inc., including an exercise of stock awards on 09/04/2025 (recorded as 82,248 shares) and multiple vesting events in 2022–2023 (1,865; 5,726; 420; 1,989). The filer certifies they are unaware of undisclosed material adverse information in the issuer.

Positive

• Detailed transaction metadata provided including broker, exchange, sale date, and aggregate market value
• Acquisition history disclosed showing compensatory origins of the securities, aiding transparency
• No sales reported in the past three months, per the filing

Negative

• Minor inconsistency in reported quantities: the 'Number of Shares To Be Sold' (92,248) vs the largest 'Amount of Securities Acquired' entry (82,248) could require clarification
• No filer identity details provided in the visible content (CIK/name/contact fields are blank), limiting traceability

Insights

Securities/Insider Transactions Analyst

TL;DR: Insider plans to sell 92,248 DD shares via Merrill Lynch on 09/04/2025; most shares originated from compensatory awards.

The filing is a routine Form 144 notice required when insiders propose public sales under Rule 144. Key facts are the proposed sale size (92,248 shares) and reported aggregate value ($7.525M), which are modest relative to the issuer's reported outstanding shares (418,716,685). Acquisition records show the holdings stem from company awards and exercises, not from open-market purchases or gifts. No prior sales in the past three months are reported. This appears procedural and compliant based on the disclosed information; there is no disclosure here of material operational or financial changes.

Corporate Governance / Compliance Specialist

TL;DR: Filing shows compliance with Rule 144 disclosure; signer affirms no undisclosed material adverse facts.

The document includes the mandatory representation that the seller lacks undisclosed material adverse information. The broker, exchange, and acquisition details are provided, and the absence of "Securities Sold During The Past 3 Months" indicates no recent aggregated sales by the filer. From a governance and compliance view, the form contains the required elements for a proposed insider sale; it does not present regulatory exceptions or noted inconsistencies within the text itself.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 3455 Peachtree Road NE STE 1000 Atlanta GA 30326	92248	7525332.00	418716685	09/04/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/04/2025	Exercise of Stock Awards	DuPont de Nemours, Inc.			82248	09/04/2025	Compensatory Payment
Common	02/14/2022	Vesting of Stock Awards	DuPont de Nemours, Inc.			1865	02/14/2022	Compensatory Payment
Common	02/16/2022	Vesting of a Stock Award	DuPont de Nemours, Inc.			5726	02/16/2022	Compensatory Payment
Common	02/19/2022	Vesting of a Stock Award	DuPont de Nemours, Inc.			420	02/19/2022	Compensatory Payment
Common	02/13/2023	Vesting of a Stock Award	DuPont de Nemours, Inc.			1989	02/13/2023	Compensatory Payment

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for DuPont de Nemours (DD) report?

The form reports a proposed sale of 92,248 shares of Common stock with an aggregate market value of $7,525,332.00, to be sold on 09/04/2025 on the NYSE through Merrill Lynch.

Who is the broker handling the proposed DD stock sale?

The filing names Merrill Lynch at 3455 Peachtree Road NE STE 1000, Atlanta, GA 30326 as the broker.

Where did the shares being sold originate according to the filing?

Acquisition entries show the shares were received from DuPont de Nemours, Inc. as compensatory stock awards and an exercise of stock awards on various dates including 09/04/2025, 2022, and 2023.

Are there any reported securities sold by the filer in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months.

Does the filer assert possession of undisclosed material information about DD?

By signing the notice, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.